Exploring Residual Concentrations of Agents in Head and Neck Cancer

Video

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Aside from cetuximab (Erbitux), researchers are working on this novel method with bevacizumab (Avastin). However, the clinical outcomes with this agent are not yet available.

Furthermore, he adds, agents including nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) are being investigated for residual concentrations. This is because these drugs are effective, but they could be improved and show activity in more patients with different doses or scheduling, Ciccolini explains.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD